Clinical trials: Recurrent Hepatocellular Cancer
Hepatocellular Carcinoma
Dendritic Cell Vaccination to Prevent Hepatocellular Carcinoma Recurrence After Liver Resection - Phase II Clinical Trial
Hepatocellular carcinoma (HCC) is the most common primary liver tumor. Surgical resection remains the first choice for early-stage HCC because the result is superior to other treatments and not limited to liver donation.
- Trial name
- NCT06193733
- Testing
- Autologous Dendritic Cell
- Where
- Taiwan
- Volunteers
- 74 people
- Sponsor
- Chang Gung Memorial Hospital
Prostate Cancer, Recurrent Adenocarcinoma
Jump: MR Simulation For Radiation Therapy Master Protocol
This is a master protocol for a prospective Phase I-II study evaluating feasibility and efficacy of incorporating magnetic resonance imaging (MRI) simulation into the planning of radiation treatments.
- Conditions
- Prostate Cancer, Recurrent Adenocarcinoma, Liver Cancer, Head and Neck Cancer
- Trial name
- JUMP (NCT04545957)
- Testing
- MRI Simulator, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 86 people
- Sponsor
- Brigham and Women's Hospital
Liver Cancer, Dropout, Patient
A Worldwide Score for Hepatocellular Cancer and Liver Transplantation
The present study has been developed with multiple aims: 1) to refine available models for liver transplantation which would be able to cover the fate of HCC candidates from an ITT point of view; 2) to develop such an approach on…
- Conditions
- Liver Cancer, Dropout, Patient, Recurrence
- Trial name
- TRAIN-SCORE (NCT03595345)
- Testing
- Liver transplantation
- Where
- Belgium
- Volunteers
- 3,100 people
- Sponsor
- European Hepatocellular Cancer Liver Transplant Group
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients with metastatic or…
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Trial name
- NCT00003557
- Testing
- dolastatin 10
- Where
- 11 sites in United States
- Volunteers
- 16 people
- Sponsor
- University of Chicago
Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase I trial to study the effectiveness of flavopiridol in treating children who have relapsed or refractory solid…
- Conditions
- Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma
- Trial name
- NCT00012181
- Testing
- alvocidib, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
Study of Thymopentin in Patients After Curative Resection of Small Hepatocellular Carcinoma
The purpose of this study is to evaluate the clinical efficacy of thymopentin on the prevention of the recurrence and metastasis of small HCC after resection.
- Trial name
- NCT00460681
- Testing
- Thymopentin
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Fudan University
Colorectal Carcinoma, Endometrial Carcinoma
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory).
- Conditions
- Colorectal Carcinoma, Endometrial Carcinoma, Melanoma, Neuroblastoma
- Trial name
- NCT04851119
- Testing
- Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint
- Where
- 21 sites in United States
- Volunteers
- 147 people
- Sponsor
- Children's Oncology Group
Recurrent Liver Carcinoma
Combination of Irreversible Electroporation and NK Immunotherapy for Recurrent Liver Cancer
The aim of this study is the safety and efficacy of irreversible electroporation (IRE) plus natural killer (NK) immunotherapy to recurrent liver cancer.
- Trial name
- NCT03008343
- Testing
- Irreversible Electroporation, Natural killer
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Recurrent Hepatocellular Carcinoma
Efficacy Analysis of Complete Laparoscopic Resection of Recurrent Hepatocellular Carcinoma
This study is aiming to evaluate the clinical efficacy of complete laparoscopic resection of recurrent hepatocellular carcinoma (HCC).
- Trial name
- NCT02613156
- Testing
- laparoscopic resection
- Volunteers
- 25 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Value of Negative 18FDG PET/CT in Milan Out, Up-to-seven in, HCC Transplant Candidates
Hepatocellular carcinoma (HCC) is a rising public health concern with few curative options but liver transplantion (LT) in highly selected cases.
- Trial name
- NCT05276037
- Testing
- Liver transplantation
- Where
- 6 sites in Belgium
- Volunteers
- 350 people
- Sponsor
- University of Liege
Liver Cancer, Liver Metastases
Impact of PVE on Patient's Long-term Survival, Complications and Cancer Recurrence.
For patients with colorectal liver metastasis (CLM), the prospect of long-term survival relies on liver resection. Wistfully, more than 75 % of patients with CLM are initially unresectable, due to an insufficient future liver…
- Trial name
- NCT03168230
- Testing
- Portal vein embolization (PVE)
- Volunteers
- 128 people
- Sponsor
- Université de Sherbrooke
Radiofrequency Ablation, Carcinoma, Hepatocellular
RFA Using Combined Bipolar and Monopolar Energy Deliver With Twin Cooled-Wet Electrodes
In this study, a dual / Twin Cooled-wet electrode was used to perform RFA therapy on residual tumors after transarterial chemo-embolization and to find out the therapeutic results.
- Trial name
- NCT04331184
- Testing
- RFA using combined bipolar and monopolar energy deliver
- Where
- South Korea
- Volunteers
- 102 people
- Sponsor
- Seoul National University Hospital
Liver Cancer, Metastatic Cancer
Heat Activated Liposomal Doxorubicin and Radiofrequency Ablation in Treating Patients With Primary or Metastatic Liver Tumors
RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00093444
- Testing
- lyso-thermosensitive liposomal doxorubicin, radiofrequency ablation
- Where
- 2 sites in United States, China
- Volunteers
- 30 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Liver Neoplasms, Liver Cirrhosis
Chemotherapy or Not, Following Complete Treatment of Hepatic Cancer in Cirrhotic Patients
Besides liver transplantation, the curative treatment of primary hepatic cancer with cirrhosis remains the surgical resection. Radiofrequency or cryotherapy currently allow local ablation of small cancer, with very good results.
- Conditions
- Liver Neoplasms, Liver Cirrhosis, Carcinoma, Hepatocellular, Recurrence
- Trial name
- GEMOXIAL (NCT00470340)
- Testing
- Oxaliplatin, gemcitabine, cisplatin, lipiodol
- Where
- France
- Volunteers
- 263 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Liver Cancer
Irinotecan in Treating Young Patients With Refractory or Recurrent Hepatoblastoma
RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00287976
- Testing
- irinotecan hydrochloride
- Where
- 22 sites in Ireland, Netherlands and 1 more
- Volunteers
- 30 people
- Sponsor
- Children's Cancer and Leukaemia Group
Liver Neoplasms
Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCC
Background: Ablation is important radical treatment in hepatocellular carcinoma (HCC). However, the 5-year recurrence rate of HCC after ablation is up to 80%.
- Trial name
- NCT06059885
- Testing
- Tislelizumab plus tyrosine kinase inhibitor
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing 302 Hospital
Childhood Hepatoblastoma, Recurrent Childhood Liver Cancer
Combination Chemotherapy With or Without Amifostine in Treating Young Patients With Liver Cancer
Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Childhood Hepatoblastoma, Recurrent Childhood Liver Cancer, Stage I Childhood Liver Cancer
- Trial name
- NCT00003994
- Testing
- therapeutic conventional surgery, cisplatin, vincristine sulfate
- Where
- United States
- Volunteers
- 277 people
- Sponsor
- Children's Oncology Group
HCC
Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model.
Primary liver cancer is one of the most common malignant tumors in the world, and more than 90% of primary liver cancers are pathologically characterized as hepatocellular carcinoma (HCC).
- Trial name
- NCT06311916
- Testing
- HAIC + Tirelizumab +lenvatinib +liver resection, liver resection
- Volunteers
- 312 people
- Sponsor
- Chen Xiaoping
Childhood Hepatocellular Carcinoma, Papillary Thyroid Cancer
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
This phase II trial studies how well sorafenib tosylate works in treating younger patients with relapsed or refractory rhabdomyosarcoma, Wilms tumor, liver cancer, or thyroid cancer.
- Conditions
- Childhood Hepatocellular Carcinoma, Papillary Thyroid Cancer, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Liver Cancer
- Trial name
- NCT01502410
- Testing
- sorafenib tosylate, pharmacological study, laboratory biomarker analysis
- Where
- 92 sites in United States, Australia and 1 more
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Liver Neoplasms, Neoplasm Metastasis
Study of NS-9 in Patients With Liver Metastases
This study is to investigate the safety of NS-9 and to see how well it is tolerated in patients with cancer that has metastasized (spread) to the liver from another primary tumor.
- Conditions
- Liver Neoplasms, Neoplasm Metastasis, Local Neoplasm Recurrences
- Trial name
- NCT00094003
- Testing
- NS-9 [Poly I: Poly C]
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- NS Pharma, Inc.